Scientists at Brigham and Women’s Hospital and Harvard Medical School developed a targeted genetic assay to better diagnose X‑linked dystonia‑parkinsonism (XDP), a debilitating neurogenetic disorder largely affecting Filipino men. The new test addresses diagnostic gaps by detecting characteristic genomic features linked to XDP that prior assays missed. Investigators reported that the targeted approach improves sensitivity and streamlines genetic confirmation, enabling earlier diagnosis and clearer patient stratification for clinical care and trials. The work aims to reduce diagnostic odysseys in affected populations and support enrollment into disease-specific research programs.